← Daily Brief
The Bell BriefFrom Dr. Jennifer Bell, DDS MAGD FICD
MEDIUMResearchTier 1

Glp-1 receptor agonists in dentistry: promise, pitfalls, and evidence gaps

SourceJournal of Dental Research (JDR)Tier 1Peer-Reviewed Research

By N. Werner, V. Pitchika, C.V. Bumm, K. Heck, M. Folwaczny, F. Schwendicke

Originally at journals.sagepub.com

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

Dentists may encounter more patients taking GLP-1 receptor agonists for obesity and diabetes, so they must understand potential oral effects, medication interactions, and altered healing responses that can affect treatment planning and outcomes.

Key points

  • GLP-1 receptor agonists prescriptions for obesity treatment rose 587% between 2019 and 2024.
  • Journal of Dental Research article reviews promise, pitfalls, and evidence gaps of GLP-1 receptor agonists in dentistry.
  • Metabolic and cardiovascular benefits of GLP-1 receptor agonists are established, while dental-specific evidence remains limited.
  • Dental professionals should assess patients on GLP-1 receptor agonists for possible medication-related oral health considerations.

Who should care

OwnerAssociateSpecialistAcademia

Read the original on Journal of Dental Research (JDR)

Full reporting and any paywall content live on journals.sagepub.com. We summarize and score; we do not republish.

Open original

Related